-
Photocure is featured in BioNJ Corporate01 Oct 2016
-
Repeat use of Blue Light Cystoscopy with Hexvix®/Cysview® shows excellent tolerabilityOslo, Norway, September 28th, 2016: Photocure ASA announced today that a study published on-line in the peer reviewed Journal of Urology, shows that there is no significant statistical difference in the frequency or grade of adverse events in patients having one Blue Light Cystoscopy with Cysview® (BLCC) versus repeat BLCC procedures.28 Sep 2016
-
Edison Issues Outlook on PhotocureEdison Group, an investment intelligence firm, has published a report on Photocure.22 Sep 2016
-
Blue Light Cystoscopy with Cysview® featured on Eyewitness NewsBlue Light Cystoscopy with Cysview® featured on the Cancer Innovations program on ABC TV in New York, NY20 Sep 2016
-
Update on management shareholdings and exercise of employee shareUpdate on management shareholdings and exercise of employee share options in Photocure ASA ("the Company")06 Sep 2016
-
Photocure Hosts Bladder Cancer Key Opinion Leader Breakfast in New York CityOslo, Norway, August 29, 2016, Photocure ASA hosted on August 25 an educational event in New York aimed at institutional investors and analysts, which focused on the treatment of bladder cancer.29 Aug 2016
-
Hexvix® marketing authorization approval in AustraliaOslo, Norway, August 24, 2016: Photocure ASA (OSE: PHO), announces that its partner and exclusive distributor, Juno Pharmaceuticals Pty Ltd, have received marketing authorization approval (MAA) for Hexvix in Australia. The market potential in the territory is estimated to be similar to the potential in the Nordics, where Photocure commercializes Hexvix with its own sales team. Hexvix is Photocure's flagship product used to aid in the diagnosis and management of bladder cancer. Under the terms of the agreement, with the MAA approval in Australia, Photocure will receive EUR 250,000 in milestone payments.24 Aug 2016
-
Results for second quarter and first half year 2016Oslo, Norway, 23 August 2016: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a sales revenue growth of 18 % to NOK 34.2 million in the second quarter of 2016 (Q2 2015: NOK 28.9 million) for the Hexvix/Cysview commercial franchise and a corresponding EBITDA of NOK 5.9 million.23 Aug 2016
-
Presentation of the second quarter 2016 results and Hexvix/Cysview updatePhotocure will present its second quarter report on Tuesday 23 August 2016 at Hotel Continental, Oslo, Norway.17 Aug 2016
-
Cysview® granted FDA approval of new prefilled syringe product packagingNew Cysview kit has an improved design providing healthcare professionals with an improved, simplified, and easy-to-use product.11 Aug 2016
-
New meta-analysis shows that Blue Light Cystoscopy with Hexvix®/Cysview® significantly reduces rate of progression in bladder cancerOslo, Norway, August 2, 2016 -- Photocure ASA announced today a new systematic review and meta-analysis on the impact of Blue Light Cystoscopy (BLC) with Hexvix® (Hexaminolevulinate) - versus White Light Cystoscopy (WLC) on progression in Non-Muscle Invasive Bladder Cancer (NMIBC).02 Aug 2016
-
Save the date: Hexvix/Cysview update and second quarter 2016 resultsOslo, Norway, 6 July 2016: Photocure ASA will present its second quarter report on Tuesday 23 August 2016 at Hotel Continental, Norway, and is proud to announce Dr. Sia Daneshmand as keynote speaker at the event. Dr. Daneshmand will provide an update on Hexvix/Cysview following the new bladder cancer guidelines from American Urological Association (AUA) and the Society of Urological Oncology (SUO), where enhanced cystoscopy including Blue Light Cystoscopy with Hexvix/ Cysview is recommended.06 Jul 2016
-
Hexvix® granted EU approval for prefilled syringe product packagingNew Hexvix kit has an improved design providing healthcare professionals with a simplified and easy-to-use product.04 Jul 2016
-
Renal & Urology News features the updated AUA/SUO Guidelines for Bladder Cancer including interviews with clinical expertsNew recommendations promise to enable clinicians to provide more individualized patient care.01 Jul 2016
-
Video featuring Blue Light Cystoscopy presented at AUA 2016The video “Blue Light Cystoscopy with Cysview: The USC Experience” presented by Dr. Sia Daneshmand, MD, is one of the 5 top-viewed videos in the VideoUrology™ Journal.13 May 2016
-
Results for first quarter 2016Oslo, Norway, 10 May 2016: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, announces its results for the first quarter 2016.10 May 2016
-
Positive clinical data on Blue Light Cystoscopy with Cysview®/Hexvix® presented at AUAOslo, Norway, May 9, 2016 -- Photocure ASA announced today new data from a prospective multicenter ongoing registry study that shows Blue Light Cystoscopy (BLC) with Cysview® increases detection rates of flat, more aggressive non-muscle invasive bladder cancer lesions (carcinoma in situ (CIS)) as well papillary lesions over white light cystoscopy (WLC) alone. The data from the prospective registry, real life, study including 175 patients, was presented at the American Urological Association (AUA) annual meeting in San Diego, CA, May 6-10, 2016.09 May 2016